Comparing the Ketogenic Effect of Coconut Oil and Different MCTs (MCT-Coco)

March 23, 2020 updated by: Université de Sherbrooke

Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides

The aim of this study is to compare the ketogenic effect of coconut oil and three MCT oils (60-40 , tricaprylin and triheptanoate) on the production of ketones in healthy adults. Each oil are evaluated individually or in combination over a 8h-period during which repeated blood sampling is performed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The study is composed of eight successive visits. Each visit consists of the consumption of one individual oil or a mixture of oils (20 g of coconut oil or 10 g of coconut oil + 10 g of MCT 60-40 or 20 g MCT 60-40 or 10 g coconut oil + 10 g tricaprylin or 20 g tricaprylin or 10 g coconut oil + 10 g triheptanoate or 20 g triheptanoate) and a 8h follow-up during which repeated blood samples are taken for laboratory analysis (plasma beta-hydroxybutyrate, acetoacetate, glucose, free fatty acids, triglycerides, total cholesterol, lactate and insulin).

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Sherbrooke, Quebec, Canada, J1H4C4
        • Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy adult over 18 y old.

Exclusion Criteria:

  • Fasting plasma glucose ≥7.0 mM (diabetics or pre-diabetics);
  • Smoking
  • Clinically-significant gastro-intestinal disease/conditions.
  • Clinically-significant liver disease/dysfunction.
  • Clinically-significant cardiac disease/conditions.
  • Clinically-significant abnormal coagulation.
  • Taking a medication that could affect lipid and glucose metabolism
  • Hypertension
  • Pregnancy or breastfeeding
  • Exercising more than 3 times a week

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Supplementation
Protocol involved seven separate but identical metabolic study days for each participant. the test substances were evaluated in random order: vehicle (Control) or 20 mL of the test oils (Coconut oil; tricaprin; tricaprylin; MCT [tricaprylin/tricaprin]; coconut oil + MCT [50:50]; Coconut oil + tricaprylin [50:50]) taken twice, once at breakfast and once at mid-day.
Dietary supplement: Coconut oil
20 g of coconut oil
Other Names:
  • Coco
Dietary supplement: Coconut oil + MCT
10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
Other Names:
  • Coco+MCT
Dietary supplement: MCT
20 g of MCT (60 of C8+40 of C10)
Dietary supplement: Coconut oil + tricaprylin
10 g coconut oil + 10 g tricaprylin
Other Names:
  • Coco+C8
Dietary supplement: Tricaprylin
20 g tricaprylin
Other Names:
  • C8
Dietary supplement: Tricaprin
20 g tricaprin
Other Names:
  • C10
Dietary supplement: Control
No supplement taken on this visit
Other Names:
  • CTL

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Ketone Concentrations
Time Frame: 8 hours

Total ketones = Plasma acetoacetate (µmol/L) + beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e. daily mean).

Samples are taken every 30 minutes on a 8 hours period. The mean is reported here.
8 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Plasma Acetoacetate/Beta-hydroxybutyrate Ratio
Time Frame: 8 hours
Plasma ratio of acetoacetate (µmol/L)/ beta-hydroxybutyrate (µmol/L) measured over a 8 hour period (i.e area-under-the-curve over 8 hours).
8 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Sherbrooke

Investigators

  • Principal Investigator: Stephen Cunnane, PhD, CSSS-IUGS - CIUSSS de L'Estrie - CHUS - Université de Sherbrooke

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2015

Primary Completion (Actual)

December 1, 2016

Study Completion (Actual)

March 1, 2017

Study Registration Dates

First Submitted

February 1, 2016

First Submitted That Met QC Criteria

February 5, 2016

First Posted (Estimate)

February 10, 2016

Study Record Updates

Last Update Posted (Actual)

April 6, 2020

Last Update Submitted That Met QC Criteria

March 23, 2020

Last Verified

March 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2016-541

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy Adults

Clinical Trials on Coconut oil

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe